The ALS Therapy Development Institute (http://www.als.net), based in Cambridge, Mass., was founded in 1999 as the ALS Therapy Development Foundation. Re-named in 2006 as a result of its collaboration with the Muscular Dystrophy Association and its Augie's Quest initiative, the Institute continues its mission to discover and develop drugs to treat ALS. A leader in ALS transgenic mouse studies, it excels in identifying novel disease targets, and screening potential treatments for ALS, as well as related neuro muscular disorders such as Alzheimer's, Parkinson's and Huntington diseases.